Search Count: 6
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.37 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBOTOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.89 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.50 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:1.47 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Resolution:2.20 Å Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |
 |
N5 Adduct Of Lsd1-Corest In Complex With Mc4455
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:3.36 Å Release Date: 2025-04-23 Classification: OXIDOREDUCTASE Ligands: A1H8N |